1. Pink Sheet
  2. >>Compliance
  3. >>Manufacturing

Outsourcing Facilities Need More Regulatory Transparency From FDA To Compound Drugs In Shortage

 
• By Joanne S. Eglovitch

Greater clarity on which drugs outsourcing facilities can compound from bulk ingredients and what good manufacturing practice requirements they will have to meet would go a long way toward enabling them to help prevent and resolve drug shortages, Pew report says. Another factor to consider: whether any loosening of restrictions during the pandemic will continue afterward.

Two pharmacists checking inventory at hospital pharmacy. Hospital staff stocktaking in drugstore.
Report Cites Reasons Why Outsourcing Facilities Not Compounding Drugs In Shortage • Source: Shutterstock

To incentivize more outsourcing facilities to compound drugs that are in shortage, the US Food and Drug Administration needs to provide greater regulatory transparency by finalizing its bulk drug compounding list and issuing final good manufacturing practice regulations for these facilities, according to a recent report from the Pew Charitable Trusts.

While the coronavirus pandemic has prompted the agency to loosen restrictions against compounding some shortage-prone drugs for emergency use, what...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By Dave Wallace

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

UK’s Plan To Become World’s Third Top Life Sciences Economy Falls Short, Says ABPI

 
• By Neena Brizmohun

The Association of the British Pharmaceutical Industry says that while the government’s newly published Life Sciences Sector Plan includes many positive commitments, they are not enough.

AI And Inertia: The Disruptors Keeping EU Regulators Awake At Night

 
• By Francesca Bruce

Data is “the new oil,” but its use will challenge regulators, while inertia is the biggest disrupter of all for European regulators, according to European Medicines Agency chiefs past and present.

AI In Manufacturing: EU To Revamp GMP Guidance In Light Of Digital Advancements

 
• By Eliza Slawther

Pharma firms are being encouraged to respond to a European Commission consultation on planned updates to its good manufacturing practice standards which reflect the “rapid advancement” of modern technologies, like AI and digital systems, in drug manufacturing.

More from Compliance